MTC U1
Alternative Names: MTC-U-1Latest Information Update: 28 Jan 2025
At a glance
- Originator Biotts
- Class Foot disorder therapies; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Pressure ulcer
- No development reported Diabetic foot ulcer; Wounds
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Diabetic-foot-ulcer in Poland (Transdermal)
- 28 Jan 2025 No recent reports of development identified for preclinical development in Wounds in Poland (Transdermal)
- 21 Sep 2022 MTC U1 is available for licensing as of 21 Sep 2022. https://biotts.com/en/our-products/ 3707319